Hospital Acquired Pneumonia Market Scope
Hospital-acquired pneumonia is defined as a lower respiratory infection, that mainly does not incubate at the time of hospital admission but also presents clinically more than 2 or 3 days after hospitalization. The most common cause of hospital-acquired pneumonia are hospitalization in an acute-care hospital within the preceding 90 days, intravenous therapy for wound care within the preceding 30 days, residence in a long-term care facility, among others. The common bacteria involved in hospital-acquired pneumonia are P aeruginosa, Staphylococcus aureus, S aureus, methicillin-resistant S aureus, among others
The market study is being classified by Type (Oral Care Kit, Toothbrush, Swab, Moisturizer, Mouth Wash and Suction Tools) and major geographies with country level break-up.
The hospital acquired pneumonia market is highly fragmented in nature with a large number of international as well as regional players operating in the market Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hospital Acquired Pneumonia market throughout the predicted period.
GlaxoSmithKline plc (United Kingdom), Achaogen, Inc. (United States), Cubist Pharmaceutical (United States), Aridis Pharmaceutical (United States), Bayer Healthcare (Germany), AstraZeneca PLC (United Kingdom), Basilea Pharmaceutica Ltd. (Switzerland), Merck & Co., Inc., (United States), Meiji Seika Pharma Co., Ltd. (Japan) and Valneva SE. (France) are some of the key players profiled in the study.
AdvanceMarketAnalytics has segmented the market of Global Hospital Acquired Pneumonia market by Type, Application and Region.
On the basis of geography, the market of Hospital Acquired Pneumonia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-user, the sub-segment i.e. Hospitals will boost the Hospital Acquired Pneumonia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Antibacterial drug will boost the Hospital Acquired Pneumonia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
In 2018, according to an article published by National Center for Biotechnology Information, the hospital-acquired pneumonia is the second most common nosocomial infection and is the utmost common hospital infection leading to death in critically ill patients. In addition, HAP is developing within 4 days of admission are defined as early hospital-acquired pneumonia. Hence, it will affect the growth of the market in the future
- Rising Demand in Combination Therapy for the Treatment of HAP
- Unmet Demand Owing to Lack of Available Treatment for MDR Microorganisms
- Incidence of HAP is more prevalent in the medical as well as surgical Intensive Care Units
- Rising Demand from Emerging Economics such as China and India
- Government Initiatives to expand the hospital Acquired Pneumonia Market
- Issue related to high Prices of Hospital-acquired pneumonia Products
- Lack of awareness of Hospital-acquired Pneumonia Drugs
- Growing cases of MDR microorganisms
Key Target AudienceManufactures Hospital acquired pneumonia Drugs, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase